Takeda Pharmaceutical - Rhonda Pacheco will become the head of Takeda's U.S. business unit on September 29, succeeding Julie Kim, who will transition to CEO in June 2026 [2] Maze Therapeutics - Shares of Maze Therapeutics increased by over 50% following positive Phase 1 data for its oral medicine MZE782, which showed good tolerance and exceeded expectations for amino acid levels [2] - Maze Therapeutics raised $150 million in a private stock offering alongside the positive results [2] Intercept Pharmaceuticals - Intercept Pharmaceuticals will withdraw its liver disease drug Ocaliva from the U.S. market at the FDA's request, which has also suspended all clinical trials for the drug due to safety concerns [2] - Ocaliva has faced scrutiny since its approval in 2016, with a black box warning added in 2018 and ongoing issues with approval for other indications [2] Soleno Therapeutics - Soleno Therapeutics' stock fell nearly 20% after a patient death was reported to the FDA, although the treating physician did not believe the drug Vykat was related to the incident [2] - The company has seen its shares lose about one-third of their value since a report by Scorpion Capital raised safety concerns about Vykat, the first approved drug for Prader-Willi syndrome [2]